
    
      Patients who have been identified as having MNGIE by genetic testing and/or reduced thymidine
      phosphorylase levels will be considered for this study. The study team physician will
      evaluate the condition of the patient and determine if they are eligible. An HLA matched
      donor is necessary for transplantation. If a suitable donor is found the transplant process
      can proceed. The patient receives immunosuppressive therapy ( 1 week in the hospital) with
      subsequent IV transfer of stem cells from the donor. The patient remains in the hospital for
      approximately 1 month to monitor the transplant. The patient is required to attend research
      visits at days 0, 100, 6m, 18m and 24 m.
    
  